Abstract
PT33 Cost-Effectiveness of Cemiplimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy As the First-Line Treatment for Advanced Non-Small Cell Lung Cancer: A Preliminary Study
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
